Complex Safety Issues Research Articles

경찰의 초동대응 체계 개선을 위한 드론 활용 방안 연구

This study explores the necessity and potential of utilizing drone technology in police operations. To address the increasing crime rates and complex safety issues in modern society, the efficient allocation of police resources and swift response are becoming imperative. This research analyzes how drone technology can meet these demands and how AI can enhance the operation of drones from both theoretical and practical perspectives. The use of drones in first response scenarios can reduce arrival times at scenes, enable monitoring over extensive areas, and facilitate accurate situation awareness, thus supporting the police in taking quicker and more effective measures. However, the integration of such technologies necessitates consideration of the legal and ethical issues that may arise, as well as preventive measures against potential technological errors and privacy invasions. The study underscores the need for a legal basis, procedural legitimacy, and safe operational conditions when actively utilizing drones and AI technology in police activities, and presents specific recommendations for this purpose.

Ensuring Integrated Security as Part of Building Digital Architecture for Energy Companies

Today, there are models for building an enterprise architecture (EA) in general and power engineering in particular. However, these models provide only a systematic approach to the formation of EA, but do not contain metrics, therefore, they do not allow comparing different versions of architectures, and even more so to build an optimal EA. In our works, we have proposed a technology for designing an optimal EA. The article is the development of this technology and the integration of an approach to solving complex safety issues in an accident. This technology can be applied to any enterprise using information and digital technologies.

OP135 CAR T-cell Therapy HTA Informs Australian Policy

IntroductionChimeric antigen receptor (CAR) T-cell therapy is offered as a once-only treatment for patients with certain cancers that are not responsive to standard treatment. While clinicians, patients and their families increasingly seek access to CAR T-cell therapy, there is no revenue stream to support access through public or private health systems.MethodsThe New South Wales (NSW) Ministry of Health and Victorian Department of Health and Human Services oversighted a health technology assessment (HTA) to explore the status and geography of regulatory frameworks supporting delivery of CAR T-cell therapy, evidence for the safety, efficacy and cost, clinical trials conducted or underway and manufacturing aspects.ResultsCAR T-cell therapies are approved in the European Union and United States of America, and being considered in Australia, Canada, China and Japan. Efficacy, safety and cost-effectiveness is limited by the size and single-arm design of early stage trials and variation between them. While overall response ranges from 36–93 percent, early results for some cancers are less favorable. Durability of treatment effect is unknown, adverse events are common and can be life-threatening and risk of delayed onset toxicity remains unknown. Treatment requires access to approved manufacturing facilities (none in Australia) and specialist clinical staff.ConclusionsCAR T-cell therapy is promising and demand is increasing, but the limited safety profile and evidence base should mitigate policy and investment decisions. Broader consideration should be given to developing, or identifying access to, manufacturing and clinical workforce capability and capacity to meet national demand. Australia is likely to encounter similar issues in other jurisdictions, such as limited evidence base and complex safety issues. Factors to be considered on a local and national basis for assessment and implementation include: (i) Regulatory support for industry; (ii) Strategies to manage uncertainties in long-term risks, benefits and costs; (iii) Access to accredited manufacturing facilities; (iv) Developing clinical and manufacturing workforce capability and capacity.

Industry Best Practice Risk based design for LPG Facility: Gap in Bangladesh practice

Bangladesh safety regulations and practice is at nascent stage. Safety distance regulation for LPG installation does not match with prescriptive standard API 2510 or other international standards. No detail technical basis is available publicly for such decision making by authority. The present study focuses on risk based design best practice in industries and gap in Bangladesh safety regulations. World LPG industry faces major accidents with fatalities and huge damages. Setting up bigger safety distance with conventional firefighting equipment is not the only mitigation measures to solve complex safety issues of LPG facilities. These two parameters do not ensure whether facility risk is tolerable and ALARP. Apart from this, safety distance and protection system design varies with facility layout, wind flows, systems reliability and site ambient conditions. For accident cases, hazards consequence modeling is carried out to calculate safety distances. Industry best practice is to apply risk based design that quantify complex risk level of a facility, propose mitigation measures and thereby risk acceptance criteria in the early phase of the project for authority approval. Many countries follow such detail regulation. Regulations of API, ISO, HSE UK and NORSOK, petroleum authority Norway have been utilized as basic standards in this paper. Gap in Bangladesh safety regulations are identified. This need to be further assessed based on industry best practice risk based design standards and practices. Without appropriate regulation, Bangladesh LPG industry and society remains in enormous intolerable personnel, environmental and economic risk.Journal of Chemical Engineering, Vol. 30, No. 1, 2017: 8-11

Post-marketing Drug Safety Measures for the Attainment of Safer and More Effective Use of Drug

In contrast with the 20th century's dramatic improvements in the direct and/or hazardous toxicity of drugs, indirect toxicity and/or long-term safety concerns such as relation of cancer risk and TNF-alpha receptor blockers have caused significant complexity in post-marketing surveillance (PMS) scenery. The post-marketing phase of drugs and their safety measures now appear to be much more complicated and heavier than decades ago. The spontaneous adverse drug reaction (ADR) reporting system which has been one of the main pillars of PMS measures for almost 50 years may have to be reviewed in terms of its effectiveness, and may need augmentation from medical data bases. Only a pharmaco-epidemiological analysis and integration of the output with a conventional spontaneous reporting approach offers a chance to satisfy the current complex safety issues. Today's tendency toward practical saturation at medical/pharmaceutical frontiers, by regulatory authorities and safety divisions of pharmaceutical companies with ever-increasing day-to-day safety information can also be pointed out. Such phenomena may actually reduce the productivity of safety measures and also jeopardize the maintenance of an acceptable risk/benefit drug ratio. To alleviate these potential negative implications, establishment of a consortium to act as a sentinel that would gather up-to-date and essential safety information, including epidemiological data, from all sources and provide it plus recommendations to all stakeholders can be suggested. Through such activities, we could expect significant improvement of drug safety measures in post-marketing phase which would effectively cover not only new drugs but also generic and bio-simulated drugs.

A review of the current evidence base for significant event analysis

To review the literature on the perceived benefits and disadvantages associated with significant event analysis (SEA) and identify reported barriers and facilitating factors. A comprehensive search of electronic databases and peer reviewed journals was conducted during June 2006. Studies which explored or measured perceptions or attitudes in relation to SEA or assessed its impact on health care quality were included. 27 studies were identified with most undertaken in UK general practice. Perceived benefits include: improved communication, enhanced team-working and awareness of others' contributions. SEA has a strong emotional resonance which may lead to a greater commitment to change. Multiple but unverifiable changes in practice and improvements in service quality were reported through participation. Disadvantages include concerns about litigation, reprisal, embarrassment and confidentiality. The reliability of SEA is questioned because it lacks a robust, standard structured method. Evidence of its impact on health care is severely limited. Barriers include a lack of training, poor team dynamics, failings in facilitation and leadership, selective topic choice and associated emotional demands. Facilitating factors include: effective practice in meetings; protected meeting time; a structured methodical approach; and strong team dynamics and leadership. A chasm exists between the high expectations for SEA and the lack of evidence of its impact. SEA may have some merit as a team-based educational tool. However, it may not be a reliable technique for investigating serious or complex safety issues in general practice. Policy makers need to be more explicit about the actual purpose of SEA.

“Keeping Each Patient Safe”:Quality Safety Teaching/Learning Packets

University of Pittsburgh Medical Center (UPMC) McKeesport developed a tool, the UPMC McKeesport Quality Safety Teaching/Learning Packet, to provide physicians, nurses, and therapists with a common language to address complex safety issues. Teaching/learning packets were developed to "keep each patient safe": by calling for help early; from falls and confusion; and from hospital-acquired infections (http://McKeesport.upmc.com/KeepingPatientsSafe.htm). In July 2002, the concept of calling for help early became a requirement at UPMC McKeesport. The code team was to be called for any significant change in status and for traditional code arrests. In 2004, a teaching/learning packet addressed the concepts of fall risk and acute (delirium) and chronic (dementia) confusion. Strategies were implemented to reduce the rate of falls through risk screening and interventions for falls and delirium. In April 2004, a teaching/learning packet was introduced to reduce hospital-acquired infections, and professionals were positioned to better address isolation, hand hygiene, central-line-associated bacteremia, Clostridium difficile, and appropriate antibiotic usage. Three quality safety teaching/learning packets, which provided the professionals in the organization with the common language (culture) to advance patient safety, accomplished rapid change and were well accepted by staff and physicians.